IGHG1 Antikörper

Produktnummer ABIN6262500

Produktdetails anti-IGHG1 Antikörper

Target: IGHG1 (Immunoglobulin Heavy Constant gamma 1 (G1m Marker) (IGHG1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IGHG1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Spezifität: IGHG1 Antibody detects endogenous levels of total IGHG1

Kreuzreaktivität: Human

Aufreinigung: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogen: A synthesized peptide derived from human IGHG1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB 1:1000-3000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: Rabbit IgG in phosphate buffered saline ,  pH 7.4, 150  mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20 °C.Stable for 12 months from date of receipt

Haltbarkeit: 12 months

Details zu IGHG1

Target: IGHG1 (Immunoglobulin Heavy Constant gamma 1 (G1m Marker) (IGHG1))

Andere Bezeichnung: IGHG1 (IGHG1 Produkte)

Synonyme: RGD1359539 antikoerper, IgG1 antikoerper, Igh-4 antikoerper, VH7183 antikoerper, immunoglobulin heavy constant gamma 1 antikoerper, immunoglobulin heavy constant gamma 1 (G1m marker) antikoerper, Ighg1 antikoerper, IGHG1 antikoerper

Hintergrund:

Description: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:17576170, PubMed:20176268).

Gene: IGHG1

UniProt: P01857